OneSource Speci.

Who are the top shareholders of the OneSource Speci.?

The top shareholders of OneSource Speci. include Tenshi Pharmaceuticals Private Limited with 17.94%, foreign institutional investors at 18.54%, and mutual funds holding 8.32%. Individual investors represent 12.96%, with Amansa Holdings Private Limited as the largest public shareholder at 3.31%.

The top shareholders of OneSource Speci. include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Tenshi Pharmaceuticals Private Limited holding the highest stake at 17.94%. Additionally, mutual funds collectively hold 8.32% through 10 schemes, while foreign institutional investors (FIIs) own 18.54% across 155 entities. The highest public shareholder is Amansa Holdings Private Limited, which holds 3.31%. Individual investors account for 12.96% of the shareholding.

Has OneSource Speci. declared dividend?

No Dividend History Available

Who are the peers of the OneSource Speci.?

OneSource Speci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Pharma, ERIS Lifescience, Alembic Pharma, Concord Biotech, and Jubilant Pharma. Key insights show excellent management risk at Concord Biotech, varied growth rates, and Divi's Lab leading with a 51.88% one-year return.

Peers: The peers of OneSource Speci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, Concord Biotech, and Jubilant Pharmo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Jubilant Pharmo. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while Below Average growth is noted for Divi's Lab., Torrent Pharma, Astrazeneca Phar, ERIS Lifescience, Alembic Pharma, and Jubilant Pharmo, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Astrazeneca Phar, ERIS Lifescience, and Alembic Pharma, while Good is seen at Torrent Pharma, and Below Average is noted for OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.88%, while the lowest is Cipla at 0.85%. OneSource Speci.'s 1-year return is not available for comparison. Additionally, Alembic Pharma and Jubilant Pharmo have negative six-month returns.

Is OneSource Speci. overvalued or undervalued?

As of May 7, 2025, OneSource Specialty is considered very expensive and overvalued, with a PE ratio of 168.15 and other high valuation metrics, despite a recent stock performance of 20.62% compared to the Sensex's 3.80%.

As of 7 May 2025, the valuation grade for OneSource Specialty has moved from does not qualify to very expensive. The company is currently overvalued, with a PE ratio of 168.15, a Price to Book Value of 54.64, and an EV to EBITDA ratio of 61.77. These figures indicate a significant premium compared to its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25, and Divi's Laboratories Ltd., with a PE ratio of 79.33.<BR><BR>In comparison to the broader market, OneSource Specialty's stock has shown a strong performance over the past month, returning 20.62% compared to the Sensex's 3.80%. However, despite this recent outperformance, the company's high valuation ratios suggest that it is not justified by its earnings potential, reinforcing the conclusion that it is overvalued in the current market environment.

What does OneSource Speci. do?

OneSource Specialty Pharma Ltd is a Large Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 4,260 Cr and a net profit of 985 Cr for March 2025. It has a market cap of INR 22,893 Cr, a P/E ratio of 171.00, and a debt-equity ratio of 1.41.

Overview: <BR>OneSource Specialty Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Large Cap company.<BR><BR>History: <BR>The company was incorporated in 2007 under the name Inbiopro Solutions Private Limited. It underwent a name change to Stelis Biopharma Private Limited following a Scheme of Amalgamation in 2014. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4,260 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 985 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 22,893 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 171.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.41 <BR>Return on Equity: 32.49% <BR>Price to Book: 55.97<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is OneSource Speci.?

As of 24th July, OneSource Specialty Pharma Ltd has a market capitalization of 22,838.00 Cr, with recent net sales of 964.88 Cr and a net loss of 42.26 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: OneSource Specialty Pharma Ltd has a market capitalization of 22,838.00 Cr and is classified as a Large Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 964.88 Cr, while the sum of Net Profit for the same period shows a loss of 42.26 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 395.71 Cr, and Total Assets are valued at 1,308.61 Cr.

How has been the historical performance of OneSource Speci.?

OneSource Speci. has shown significant growth in net sales, increasing from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025, despite facing challenges in profitability, with a profit before tax of -67.07 Cr in March 2025. Total assets rose to 7,550.24 Cr, but cash flow from operating activities remained negative at -67.00 Cr.

Answer:<BR>The historical performance of OneSource Speci. shows significant fluctuations in key financial metrics over the past four years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>OneSource Speci. experienced a dramatic increase in net sales, rising from 128.18 Cr in March 2022 to 1,444.85 Cr in March 2025. This surge in total operating income followed a similar trend, moving from 171.92 Cr in March 2024 to 1,444.85 Cr in March 2025. However, the company's total expenditure also escalated, reaching 978.34 Cr in March 2025, up from 260.16 Cr in March 2024. Despite the growth in revenue, the operating profit (PBDIT) improved to 483.98 Cr in March 2025 from a loss of 84.01 Cr in March 2024. Nevertheless, the company reported a profit before tax of -67.07 Cr in March 2025, an improvement from -365.70 Cr in March 2024. The profit after tax also showed a slight recovery, with a loss of -17.28 Cr in March 2025 compared to -365.70 Cr in March 2024. The total assets of OneSource Speci. increased significantly to 7,550.24 Cr in March 2025 from 1,308.61 Cr in March 2024, while total liabilities also rose to 7,550.24 Cr. The cash flow from operating activities remained negative at -67.00 Cr in March 2025, although the net cash inflow improved to 143.00 Cr, indicating a positive shift in cash management. Overall, while OneSource Speci. has shown substantial growth in sales and operating income, it continues to face challenges in profitability and cash flow management.

When is the next results date for OneSource Specialty Pharma Ltd?

The next results date for OneSource Specialty Pharma Ltd is 13 May 2026.

The next results date for OneSource Specialty Pharma Ltd is scheduled for 13 May 2026.

Are OneSource Specialty Pharma Ltd latest results good or bad?

OneSource Specialty Pharma Ltd's latest results show strong revenue growth of 47.49% to ₹428.22 crores, but a significant decline in net profit by 95.33% and compressed operating margins raise concerns about profitability and financial health. Investors should be cautious despite the positive revenue trends.

OneSource Specialty Pharma Ltd's latest results present a mixed picture, highlighting both significant challenges and some positive developments. <BR><BR>On the positive side, the company achieved a remarkable sequential revenue growth of 47.49%, reaching net sales of ₹428.22 crores, which is the highest quarterly figure on record. This suggests strong demand or successful product launches in the short term.<BR><BR>However, the profitability metrics are concerning. The net profit for Q4 FY26 was ₹4.60 crores, which represents a staggering decline of 95.33% year-on-year. Additionally, the operating margin has significantly compressed from 42.85% to 21.47% over the same period, indicating substantial pressure on profitability. The return on equity (ROE) is also weak at 2.44%, reflecting poor capital efficiency.<BR><BR>Overall, while there are signs of operational recovery in terms of revenue growth, the severe decline in profitability and margins raises critical concerns about the company's financial health and ability to sustain growth. Investors should be cautious, as the results suggest that despite the revenue increase, the company is struggling to convert that growth into meaningful profits.

Should I buy, sell or hold OneSource Specialty Pharma Ltd?

Why is OneSource Specialty Pharma Ltd falling/rising?

As of 19-May, OneSource Specialty Pharma Ltd's stock price is rising to 1,853.60, reflecting a 2.48% increase. This upward trend is driven by strong recent performance, increased investor interest, and healthy long-term growth metrics.

As of 19-May, OneSource Specialty Pharma Ltd's stock price is rising, currently at 1,853.60, reflecting a change of 44.8 (2.48%) upwards. This positive movement can be attributed to several factors. The stock has outperformed the sector by 1.51% today and has shown strong performance over the past month, with a return of +20.34%, while the broader market has declined by -4.19%. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bullish trend.<BR><BR>Investor participation has also increased, with a delivery volume of 1.82 lacs on 18 May, which is up by 28.09% compared to the 5-day average. This suggests growing interest and confidence among investors. Furthermore, the company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 185.90% and operating profit rising by 67.54%. <BR><BR>Despite some negative factors, such as low return on equity and a weak ability to service debt, the stock's recent performance and positive growth metrics have contributed to its rising price. Overall, the combination of strong recent returns, increased investor participation, and healthy sales growth has led to the upward movement in OneSource Specialty Pharma Ltd's stock price.

Which are the latest news on OneSource Speci.?